|Articles|August 1, 2019
- Pharmaceutical Executive-08-01-2019
- Volume 39
- Issue 8
Pharmaceutical Executive, August 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive August 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 6 years ago
A Look Back & Forward on Innovationabout 6 years ago
Routes to Exclusivity in Cell-Based Therapy Developmentabout 6 years ago
Gene Therapy: Managing the Clinical Trial Minefieldsabout 6 years ago
The Call to Cure: Geoff MacKay, AVROBIOabout 6 years ago
Four Takeaways from the Zolgensma Pricing Stormabout 6 years ago
FDA Faces ‘Explosion’ in Growth of Gene Therapiesabout 6 years ago
Mapping Out the Future of Cell and Gene Therapyabout 6 years ago
High-Stakes Manufacturing: Mitigating the Risksabout 6 years ago
Gene Therapy: How ‘Advanced’ is Europe?about 6 years ago
Luxturna: A Vision for Curative Therapy AccessNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Merck Planning $70 Billion Investment for US Expansion
2
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
3
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
4
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
5
